STAT

Listen: Unicorn growth spurts, Amgen’s future, & mice on Twitter

Who puts horns on unicorns? How do graying drug companies find green ideas? And what would mice tweet? Find out on the new episode of "The Readout LOUD." Listen now:

Who puts horns on unicorns? How do graying drug companies find green ideas? And what would mice tweet?

We discuss all that, comes by to explain the inspiration behind his mini-viral Twitter account and how it has (arguably) changed scientific discourse online. Finally, we embark upon a lightning round, touching the latest Democratic drug pricing plan, the fortunes of Purdue Pharma, and Martin Shkreli’s business acumen.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks